We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Probe Detects Breast Cancer Margins

By HospiMedica International staff writers
Posted on 03 Jul 2012
A new device uses radiofrequency (RF) spectroscopy to differentiate tissue types, helping surgeons assure that all cancerous tissue is removed around a breast cancer site. More...


The MarginProbe system enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The device works by emitting an RF electric field and sensing the returning signal from the tissue under evaluation. The device is based on the fact that tumors exhibit greater vascularization, a different polarization of the cell membrane, enlarged nucleus volume, rapid copying of DNA, rapid growth of new blood vessels (angiogenesis), and a decrease in the connectivity from one cell to another.

Since these and other and other anatomical differences are evident when compared to healthy tissue, the electromagnetic signature is different as well. The device captures these minute differences in electromagnetic properties via a disposable probe unit that houses a highly responsive fringe field sensor (FFS) that both emits the precisely controlled electromagnetic field and captures the tissue response. The surgeon runs a series of measurements on each margin, collecting data for the entire specimen.

An external console houses proprietary software that captures the signal, compares it to the internal database, and characterizes the specimen, reporting results on the high-resolution display. The display lists each reading sequentially, which allows for grouping measurements from the same margin. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, significantly reducing the potential for positive margins remaining after the initial lumpectomy. The MarginProbe System is a product of Dune Medical (Framingham, MA, USA), and is pending approval by the US food and Drug Administration (FDA).

“We believe that the MarginProbe System will give surgeons a powerful tool in their fight against breast cancer and provide women a substantially better chance of avoiding additional surgeries,” said Dan Levangie, CEO of Dune Medical. “We will work closely with the FDA to complete the approval process and intend to launch the MarginProbe System in the U.S. immediately thereafter.”

RF Spectroscopy is concerned with the measurement of the intervals between atomic or molecular energy levels that are separated by radio frequency wavelengths. It is used in such industries as the semiconductor, pharmaceutical, aerospace, and fuel cell fields.

Related Links:
Dune Medical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.